INDRANIBOther Agricultural Products
Indrayani Biotech Ltd — Profit & Loss Statement
₹7.23
-2.77%
Indrayani Biotech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.01 Cr | 0.00 | — |
| Tax Rate For Calcs | 0.30 | 0.05 | 0.03 | 0.00 | — |
| Normalized EBITDA | 9.39 Cr | 24.66 Cr | 21.10 Cr | 6.94 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.45 Cr | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.45 Cr | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | -6.11 Cr | 10.42 Cr | 8.74 Cr | 4.44 Cr | — |
| Reconciled Depreciation | 3.37 Cr | 3.81 Cr | 3.35 Cr | 0.66 Cr | — |
| Reconciled Cost Of Revenue | 82.77 Cr | 97.13 Cr | 102.21 Cr | 41.04 Cr | — |
| EBITDA | 9.39 Cr | 24.66 Cr | 20.65 Cr | 6.94 Cr | — |
| EBIT | 6.02 Cr | 20.86 Cr | 17.31 Cr | 6.28 Cr | — |
| Net Interest Income | -11.76 Cr | -9.88 Cr | -2.09 Cr | -1.78 Cr | — |
| Interest Expense | 11.76 Cr | 9.88 Cr | 5.00 Cr | 1.83 Cr | — |
| Normalized Income | -6.11 Cr | 10.42 Cr | 9.17 Cr | 4.44 Cr | — |
| Net Income From Continuing And Discontinued Operation | -6.11 Cr | 10.42 Cr | 8.74 Cr | 4.44 Cr | — |
| Total Expenses | 127.33 Cr | 146.58 Cr | 148.96 Cr | 55.45 Cr | — |
| Diluted NI Availto Com Stockholders | -6.11 Cr | 10.42 Cr | 8.74 Cr | 4.44 Cr | — |
| Net Income Common Stockholders | -6.11 Cr | 10.42 Cr | 8.74 Cr | 4.44 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -6.11 Cr | 10.42 Cr | 8.74 Cr | 4.44 Cr | — |
| Net Income Including Noncontrolling Interests | -6.11 Cr | 10.42 Cr | 11.93 Cr | 4.44 Cr | — |
| Net Income Discontinuous Operations | 0.00 | — | 0.00 | 0.00 | — |
| Net Income Continuous Operations | -6.11 Cr | 10.42 Cr | 11.93 Cr | 4.44 Cr | — |
| Tax Provision | 0.36 Cr | 0.55 Cr | 0.38 Cr | 0.01 Cr | — |
| Pretax Income | -5.74 Cr | 10.97 Cr | 12.31 Cr | 4.45 Cr | — |
| Other Non Operating Income Expenses | 3.13 Cr | 1.21 Cr | 0.79 Cr | 0.10 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.45 Cr | 0.00 | — |
| Net Non Operating Interest Income Expense | -11.76 Cr | -9.88 Cr | -2.09 Cr | -1.78 Cr | — |
| Interest Expense Non Operating | 11.76 Cr | 9.88 Cr | 5.00 Cr | 1.83 Cr | — |
| Operating Income | 2.89 Cr | 19.64 Cr | 13.97 Cr | 6.12 Cr | — |
| Operating Expense | 44.56 Cr | 49.45 Cr | 46.74 Cr | 14.40 Cr | — |
| Other Operating Expenses | 20.73 Cr | 21.72 Cr | 15.22 Cr | 2.73 Cr | — |
| Depreciation And Amortization In Income Statement | 3.37 Cr | 3.80 Cr | 3.35 Cr | 0.66 Cr | — |
| Depreciation Income Statement | 3.37 Cr | 3.80 Cr | 3.35 Cr | 0.66 Cr | — |
| Gross Profit | 47.46 Cr | 69.09 Cr | 60.71 Cr | 20.53 Cr | — |
| Cost Of Revenue | 82.77 Cr | 97.13 Cr | 102.21 Cr | 41.04 Cr | — |
| Total Revenue | 130.23 Cr | 166.23 Cr | 162.93 Cr | 61.57 Cr | — |
| Operating Revenue | 130.23 Cr | 166.23 Cr | 162.93 Cr | 61.57 Cr | — |
| Interest Income | — | 0.20 Cr | 3.55 Cr | 0.11 Cr | 0.16 Cr |
| Rent Expense Supplemental | — | 1.09 Cr | 0.86 Cr | 0.39 Cr | 0.43 Cr |
| Diluted Average Shares | — | 4.55 Cr | 4.35 Cr | 3.42 Cr | 3.56 Cr |
| Basic Average Shares | — | 4.55 Cr | 3.42 Cr | 3.42 Cr | 3.56 Cr |
| Diluted EPS | — | 1.40 | 2.05 | 1.30 | -3.15 |
| Basic EPS | — | 1.40 | 2.55 | 1.30 | -3.15 |
| Minority Interests | — | -4.06 Cr | -3.19 Cr | — | 0.09 Cr |
| Impairment Of Capital Assets | — | 0.00 | 0.50 Cr | 0.00 | — |
| Total Other Finance Cost | — | 0.21 Cr | 0.64 Cr | 0.06 Cr | 0.06 Cr |
| Interest Income Non Operating | — | 0.20 Cr | 3.55 Cr | 0.11 Cr | 0.16 Cr |
| Selling General And Administration | — | 1.84 Cr | 3.78 Cr | 0.41 Cr | 0.71 Cr |
| Selling And Marketing Expense | — | 0.82 Cr | 0.89 Cr | 0.17 Cr | 0.32 Cr |
| General And Administrative Expense | — | 1.02 Cr | 2.89 Cr | 0.24 Cr | 0.40 Cr |
| Rent And Landing Fees | — | 1.09 Cr | 0.86 Cr | 0.39 Cr | 0.43 Cr |
| Net Income Extraordinary | — | — | 0.00 | 0.00 | — |
| Other Special Charges | — | — | 0.45 Cr | — | 4.11 Cr |
| Write Off | — | — | 0.00 | 0.00 | 0.49 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Indrayani Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.